The key targets and pathways of TGGR in the prevention and treatment of depression and the preliminary validation of this target and pathway of action, analyzed with a combination of network pharmacology and transcriptomics. (A) Cross-targets of TGGR and depression in network pharmacology and cross-targets of transcriptomic differential genes. (B) Cross-target GO enrichment analysis. (C) The top 10 KEGG enrichment pathways for cross-targets. (D,E) Expression of SIRT1 and PGC-1α in mouse hippocampus (immunohistochemical staining). (F) Western blot analysis of AMPK, SIRT1, and PGC-1α in the hippocampus of mice in each group. Protein expression was normalized to β-actin for quantitative analysis, and its value expressed as an average (G). Normalization of the data to β-actin. Values are expressed as average ± SD. ** p < 0.01 was significantly different from the control group, and #
p < 0.05 and ##
p < 0.01 were significantly different from model group.